Carnitine Palmitoyltransferase-1 (CPT1) has recently emerged as an attractive therapeutic target against insulin resistance, based on a theory derived from the Randle Cycle that inhibition of CPT1 activity may promote the redirection of mitochondrial substrate metabolism from fatty acids to glucose, thus ameliorating insulin resistance [3]. This evidence concerns the gene CPT1A and Insulin resistance.